2.43
+0.05(+2.10%)
Currency In USD
| Previous Close | 2.38 |
| Open | 2.38 |
| Day High | 2.48 |
| Day Low | 2.34 |
| 52-Week High | 5.59 |
| 52-Week Low | 1.84 |
| Volume | 110,708 |
| Average Volume | 193,718 |
| Market Cap | 84.28M |
| PE | -1.96 |
| EPS | -1.24 |
| Moving Average 50 Days | 2.59 |
| Moving Average 200 Days | 3.82 |
| Change | 0.05 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.62 as of May 09, 2025 at a share price of $2.43. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $270 as of May 09, 2025 at a share price of $2.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatme
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
GlobeNewswire Inc.
Apr 21, 2025 3:19 PM GMT
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVE
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
GlobeNewswire Inc.
Mar 07, 2025 1:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a trea